Tuesday 20 April 2021
News ID: 88002
Publish Date: 26 February 2021 - 22:09
TEHRAN (FNA)- Head of Iran’s Razi Serum and Vaccine Research Institute Ali Eshaqi said that the second Iran-made coronavirus vaccine, COV-Pars, produced by the Institute has been licensed by the Iran Food and Drug Administration (IFDA) to start clinical trial on volunteers.
"The license for conducting phase one of the clinical trial of the recombinant vaccine of Spike Covid-19 protein (Razi COV-Pars) made by Razi Vaccine and Serum Research Institute has been issued by the IFDA,” Eshaqi has said .
Meantime, Mohammad Esmayeel Motlaq, a senior advisor to the Iranian deputy health minister, said that the vaccine which is being produced by Barekat foundation, COV-Iran, is able to contain the British coronavirus mutation, and mentioned that mass-production of the vaccine is expected to start in April.
Iranian Health Minister Saeed Namaki said that the country will start mass-production of its home-made coronavirus vaccine in April, adding that Iran will start vaccine exports after satiating domestic needs.
"We anticipate production of the national vaccine to start in April and we will turn into an exporter of the vaccine in the region after meeting internal needs,” Namaki said.
He, meantime, underlined continued imports of COVID-19 vaccine, adding that 250,000 doses of the vaccine will be imported soon.

* Comment: